annb0t
Top 20
Shares of uniQure QURE were up 7.08% during market hours after the company announced that its partner CSL Behring received FDA approval for one-time gene therapy, Hemgenix (etranacogene dezaparvovec-drlb), for treating hemophilia B patients above 18 years.
uniQure conducted the research and clinical development for the product. CSL Behring is a subsidiary of CSL Limited.
Hemgenix is the first FDA-approved gene therapy for treating hemophilia B.
The biologics license application (BLA) for etra...
>>> Read more: uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
uniQure conducted the research and clinical development for the product. CSL Behring is a subsidiary of CSL Limited.
Hemgenix is the first FDA-approved gene therapy for treating hemophilia B.
The biologics license application (BLA) for etra...
>>> Read more: uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
